16 to 21 Project

16 to 21 Project Limited

ActiveLatest figures: 2025Abridged accountsCompany only14 years on the register

Private limited company registered in London, classed under “Other human health activities”.

Headline figures

FY to Sept 2025 · Company only

Turnover

For subscribers

Profit after tax

—

Not filed: small-company exemption

Net assets

For subscribers

Cash

For subscribers

Employees

For subscribers

Retained reserves

For subscribers

3 findings from the figures, in plain English

Written by rules from the figures on this page. Not a forecast or a credit opinion.

Pro

Every figure for all 5 years

“—” means we did not find the figure in a source; it is never filled with an estimate.

From the filed balance sheets · £

Balance sheet	2022	2023	2024	2025
Fixed assets
Current assets
of which debtors
of which cash
Creditors due within a year
Net current assets
Net assets
Ratios
Current ratioCurrent assets for every £1 owed within a year
Cash ratioCash for every £1 owed within a year
Creditors to assetsEverything owed to creditors as a share of fixed plus current assets

7 balance-sheet lines and 3 ratios, every year

A ratio appears only for years where every line it needs was filed. Lines are as tagged in the accounts; nothing is added up or estimated.

›What does 16 to 21 Project do?

Private limited company registered in London, classed under “Other human health activities”.

›How much turnover does 16 to 21 Project make?

Answered in the full report

›Is 16 to 21 Project profitable?

16 to 21 Project's profit isn't public: small companies may file without a profit and loss account.

›How many people work at 16 to 21 Project?

Answered in the full report

›Where is 16 to 21 Project based?

Its registered office is Flat 14 Centurion Building, 376 Queenstown Road, London, London, SW8 4NW, in London.

›When was 16 to 21 Project founded?

16 to 21 Project Limited was incorporated on 28 September 2012.

›Is 16 to 21 Project still trading?

The register lists 16 to 21 Project Limited as active.